Pozen (Nasdaq: POZN) turned a profit in the fourth quarter of 2005 thanks to a $20 million milestone payment from GlaxoSmithKline.

The payment was made following the successful submission of a new drug application for headache treatment Trexima to the FDA.

Pozen reported net earnings of $16.1 million for the quarter. In the same quarter of 2004, Pozen lost $8.4 million.

Pozen: www.Pozen.com